Skip to main content

Table 4 Cox regression analyses of potential factors associated with overall survival in patients with metastatic colorectal cancer (n = 122)

From: A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

 

HR

95% CI

p

Univariate analysis: Covariate

 Gender (female)

0.68

0.44–1.06

0.092

 Age, years

1.01

0.99–1.03

0.55

 Vascular endothelial growth factor, μg/L

2.09

1.10–3.99

0.025

 Ctrough bevacizumab <15.5 mg/L

2.34

1.52–3.58

9.9 × 10−5

 Log(carcinoembryonic antigen), μg/L

1.21

1.10–1.34

9.8 × 10−5

 IL17A polymorphism (A carriers)

0.86

0.56–1.30

0.47

 IL17F polymorphism (AG)

1.80

0.87–3.73

0.11

 IL-1β, pg/mL

1.23

0.69–2.21

0.48

 IL-4, pg/mL

1.00

0.99–1.01

0.96

 IL-6, pg/mL

1.00

0.99–1.00

0.49

 IL-10, pg/mL

1.00

0.99–1.02

0.61

 IL-17A, pg/mL

1.01

0.99–1.03

0.22

 IL-17F, pg/mL

0.99

0.97–1.01

0.34

 IL-22, pg/mL

1.07

0.99–1.15

0.057

 IL-31, pg/mL

1.00

1.00–1.004

0.019

 IL-33, pg/mL

1.00

0.99–1.00

0.95

 sCD40L, pg/mL

1.00

0.86–1.06

0.83

 Tumor necrosis factorα, pg/mL

0.97

0.86–1.09

0.61

Multivariate analysis: Covariate

 Ctrough bevacizumab <15.5 mg/L

1.88

1.19–2.97

0.0064

 Log(CEA), μg/L

1.15

1.04–1.28

0.0057

  1. Abbreviations: HR hazard ratio, 95% CI 95% confidence interval, C trough trough concentration of bevacizumab before second infusion